N. Wong

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Nathan D. Wong, N Wong, N D Wong, Nathan Wong, N. D. Wong, Nathan D Wong
Publication record
589 papers · 62,016 citations · H-index 86

PAPERS

Knowledge Gaps, Challenges, and Opportunities in Health and Prevention Research for Asian Americans, Native Hawaiians, and Pacific Islanders: A Report From the 2021 National Institutes of Health Workshop
202278 citationsauthor #29
Editors’ page‐March 2022
20220 citationsauthor #2
Prevalence of statin intolerance: a meta-analysis
2022333 citationsauthor #4
Temporal changes in risk of cardiovascular events in people with newly diagnosed type 2 diabetes with and without cardiovascular disease.
20225 citationsauthor #9
Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India.
20211 citationsauthor #32
Editors’ page - March 2021 issue
20210 citationsauthor #2
Perceptions and Barriers on the Use of Proprotein Subtilisin/Kexin Type 9 Inhibitors in Heterozygous Familial Hypercholesterolemia (From a Survey of Primary Care Physicians and Cardiologists).
20218 citationsauthor #1
Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases - A position paper from the International Lipid Expert Panel (ILEP).
202158 citationsauthor #11
Statin and Icosapent Ethyl Use and Lipid Control in US Adults with Diabetes According to DM Risk Groups, Sex and Ethnicity in the NIH Precision Medicine Initiative All of Us Study
20210 citationsauthor #4
COMPARISON OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK PREDICTION BY LIPOPROTEIN(A) LEVELS BETWEEN PERSONS WITH AND WITHOUT PRIOR CARDIOVASCULAR DISEASE: THE UK BIOBANK
20210 citationsauthor #1
Metabolic syndrome, fatty liver, and artificial intelligence-based epicardial adipose tissue measures predict long-term risk of cardiac events: a prospective study
202149 citationsauthor #2
Cascade Screening and Treatment Initiation in Young Adults with Heterozygous Familial Hypercholesterolemia
20218 citationsauthor #4
Erratum to 'Lipid Treatment and Goal Attainment Characteristics among Persons with Atherosclerotic Cardiovascular Disease in the United States' [American Journal of Preventive Cardiology 1C (2020) 100010].
20211 citationsauthor #5
Association of inflammatory markers and lipoprotein particle subclasses with progression of coronary artery calcium: The multi-ethnic study of atherosclerosis.
202117 citationsauthor #7
Identification and Predictors for Cardiovascular Disease Risk Equivalents Among Adults With Diabetes
202119 citationsauthor #8
Awareness, diagnosis and treatment of heterozygous familial hypercholesterolemia (HeFH) - Results of a US national survey.
202111 citationsauthor #4
ASPC Manual of Preventive Cardiology
20212 citationsauthor #1
Novel biomarker panel measuring endothelial injury identifies patients at risk of coronary artery syndrome and discordance with low-density lipoprotein cholesterol
20210 citationsauthor #5
Breast Arterial Calcification and Cardiovascular Risk Among Postmenopausal Women
20210 citationsauthor #9
Metabolically Healthy/Unhealthy Overweight/Obesity Associations With Incident Heart Failure in Postmenopausal Women
202114 citationsauthor #11
Importance of applying treatment data to ascertain type 1 diabetes cases in health registries
20210 citationsauthor #2
IMPAIRED FLOW-MEDIATED DILATATION (FMD) DID NOT PREDICT LONG-TERM CARDIOVASCULAR EVENTS OR ATHEROSCLEROSIS PROGRESSION IN THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA) STUDY
20210 citationsauthor #4
ASSOCIATION OF LIVER FIBROSIS WITH CARDIOVASCULAR DISEASE AND TOTAL MORTALITY IN US ADULTS ACCORDING TO DIABETES STATUS 1999-2014
20210 citationsauthor #1
A REAL-WORLD ASSESSMENT OF PATIENT CHARACTERISTICS AND TREATMENT PATTERNS AMONG PATIENTS WITH LIPOPROTEIN(A) MEASUREMENT AND RECEIVING PRIMARY AND SECONDARY PREVENTION FOR CARDIOVASCULAR DISEASE IN THE US
20212 citationsauthor #8
Editors’ page for Sept 2021 issue
20210 citationsauthor #2
When is it Appropriate to Lower Low Density Lipoprotein-Cholesterol Levels to <30 mg/dL?
20211 citationsauthor #1
Editor's Message
20210 citationsauthor #2
Assessment of The High risk and unmEt Need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource use, cost, and burden of illness in a commercially insured population.
20213 citationsauthor #5
Association of cardiovascular health with mortality among COPD patients: National Health and Nutrition Examination Survey III.
20217 citationsauthor #4
Cardiovascular Outcomes with GLP-1 Receptor Agonists Versus SGLT-2 Inhibitors in Patients with Type 2 Diabetes.
202123 citationsauthor #8
Relation of First and Total Recurrent Atherosclerotic Cardiovascular Disease Events to Increased Lipoprotein(a) Levels among Statin Treated Adults with Cardiovascular Disease.
202115 citationsauthor #1
Newer Treatments and Glycemic Control in US Adults With Diabetes Across Risk Groups, Sex, and Ethnicity: The NIH Precision Medicine Initiative (All Of Us Study)
20210 citationsauthor #4
The Rationale for an LDL-Cholesterol Goal < 30 mg/dl: Expert Recommendations From the Lipid Association of India
20200 citationsauthor #7
METABOLIC SYNDROME AND AUTOMATED EPICARDIAL ADIPOSE TISSUE MEASURES PREDICT LONG-TERM RISK OF CARDIAC EVENTS IN ASYMPTOMATIC SUBJECTS
20200 citationsauthor #2
Abstract P285: Sociodemographic and Metabolic Risk Characteristics Associated with Metabolic Weight Categories in the Women's Health Initiative
20200 citationsauthor #7
Prevalence of US Adults with Triglycerides ≥ 150 mg/dl: NHANES 2007–2014
202062 citationsauthor #5
Predicting Long-Term Absence of Coronary Artery Calcium in Metabolic Syndrome and Diabetes: The MESA Study.
202023 citationsauthor #2
Abstract P441: Oral Glucose Tolerance Test Detects Diabetes at Early Stages
20200 citationsauthor #2
A treatment-based algorithm for identification of diabetes type in the National Health and Nutrition Examination Survey
202015 citationsauthor #4
Machine learning integration of circulating and imaging biomarkers for explainable patient-specific prediction of cardiac events: A prospective study.
202048 citationsauthor #16
The costs outweigh the benefits: seeing side-effects online may decrease adherence to statins
202010 citationsauthor #6
Faculty Opinions recommendation of Cardiovascular disease risk prediction using automated machine learning: A prospective study of 423,604 UK Biobank participants.
20201 citationsauthor #1
N-terminal Pro B-type Natriuretic Peptide and High-sensitivity Cardiac Troponin as Markers for Heart Failure and Cardiovascular Disease Risks According to Glucose Status (from the Multi-Ethnic Study of Atherosclerosis [MESA]).
202033 citationsauthor #9
Disparities in the Use of Preventive Medications and Risk Factor Control in Persons with Coronary Heart Disease: National Health and Nutrition Examination Survey 2011-2016
20200 citationsauthor #5
LONG-TERM PREDICTION OF CARDIAC EVENTS IN ASYMPTOMATIC SUBJECTS BY INTEGRATING NOVEL CIRCULATING AND IMAGING BIOMARKERS USING MACHINE LEARNING
20200 citationsauthor #12
Abstract 14606: Endothelial Injury Biomarkers and Risk Factors Associated With Discordant Risk of Acute Coronary Syndrome Despite Controlled Low-density Lipoprotein Cholesterol Identified by a Novel Coronary Artery Disease Predictive Algorithm
20200 citationsauthor #5
Abstract 17098: Liver Fibrosis and Associated Cardiovascular Disease Risk and Its Predictors Among US Adults With and Without Diabetes
20201 citationsauthor #1
Abstract 17348: Cardiovascular Risk Prediction in Diabetes From Machine Learning: The ACCORD Study
20201 citationsauthor #4
Cardiodiabetology: Reducing Risks to Optimize Cardiovascular Disease Outcomes
20200 citationsauthor #1
Metabolic Syndrome, Fatty Liver, And Artificial Intelligence-based Epicardial Adipose Tissue Measures Predict Long-term Risk Of Cardiac Events
20201 citationsauthor #2
Development of a Risk Score for Atrial Fibrillation in Adults With Diabetes Mellitus (from the ACCORD Study).
202020 citationsauthor #3
The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP).
2020108 citationsauthor #73
Lipoprotein(a) and ASCVD risk.
202010 citationsauthor #41
Incidence of diabetes according to metabolically healthy or unhealthy normal weight or overweight/obesity in postmenopausal women: the Women's Health Initiative.
202013 citationsauthor #10
LIPOPROTEIN (A) RELATED RISK FOR ALL-CAUSE AND CARDIOVASCULAR MORTALITY IN US ADULTS ACCORDING TO DIABETES STATUS
20200 citationsauthor #3
Deep Learning–Based Quantification of Epicardial Adipose Tissue Volume and Attenuation Predicts Major Adverse Cardiovascular Events in Asymptomatic Subjects
2020124 citationsauthor #12
Regional differences in the management of cardiovascular risk factors among adults with diabetes: An evaluation of the Diabetes Collaborative Registry.
20204 citationsauthor #2
Assessment of the high risk and unmet need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource utilization, cost and burden of illness in the Diabetes Collaborative Registry
20207 citationsauthor #8
Cardiovascular risk assessment: The foundation of preventive cardiology
202024 citationsauthor #1
Apolipoprotein B as a Predictor of CVD.
20204 citationsauthor #41
Retrospective Cohort Study in Patients with Familial Hypercholesterolemia, Premature Major Adverse Cardiovascular Events, Depression, Lipoprotein(a), and Highly Sensitive C-Reactive Protein
20200 citationsauthor #4
The Evolving Understanding and Approach to Residual Cardiovascular Risk Management
2020143 citationsauthor #4
High Sensitivity C-Reactive Protein.
20200 citationsauthor #41
TOTAL ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) RESIDUAL RISK ASSOCIATED WITH INCREASED LIPOPROTEIN(A) LEVELS AMONG STATIN TREATED ADULTS WITH CARDIOVASCULAR DISEASE
20200 citationsauthor #1
Evaluating Multisite Atherosclerosis and its Progression: Ready for Prime Time?
20203 citationsauthor #1
The HDL Quandary
20200 citationsauthor #3
Perceptions and Barriers on the Use of PCSK9 Inhibitors in Heterozygous Familial Hypercholesterolemia
20201 citationsauthor #5
Both Cardiologists and Primary Care Physicians Lack Awareness in How to Recognize and Treat Heterozygous Familial Hypercholesterolemia†
20200 citationsauthor #5
N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE IN THE PREDICTION OF REDUCED CORONARY FLOW VELOCITY RESERVE IN ASYMPTOMATIC TYPE 2 DIABETIC PATIENTS
20200 citationsauthor #7
HOW WELL DO CARDIOLOGISTS AND PRIMARY CARE PHYSICIANS RECOGNIZE AND TREAT HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: A SURVEY FROM THE NATIONAL LIPID ASSOCIATION
20200 citationsauthor #2
Abstract 163: Association of Diabetes With Coronary Artery Calcium in South Asians, African Americans, Caucasians, Chinese, and Hispanics: The Multi-Ethnic Study of Atherosclerosis (MESA) and the Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study
20200 citationsauthor #10
Association of Coronary Calcium, Carotid Wall Thickness, and Carotid Plaque Progression with Low Density Lipoprotein and High Density Lipoprotein Particle Concentration Measured by Ion Mobility (From Multiethnic Study of Atherosclerosis [MESA]).
202013 citationsauthor #6
Nutraceutical support in heart failure: a position paper of the International Lipid Expert Panel (ILEP)
202046 citationsauthor #9
1417-P: Lipoprotein(a)-Associated Residual Atherosclerotic Cardiovascular Disease Risk in Patients with Cardiovascular Disease on Statin Therapy by Diabetes Status
20200 citationsauthor #4
Racial and Geographic Disparities in Internet Use in the U.S. Among Patients With Hypertension or Diabetes: Implications for Telehealth in the Era of COVID-19
202057 citationsauthor #7
Low Density Lipoprotein Cholesterol Targets in Secondary Prevention of Atherosclerotic Cardiovascular Disease.
20204 citationsauthor #41
Five-Year Residual Atherosclerotic Cardiovascular Disease Risk Prediction Model for Statin Treated Patients with Known Cardiovascular Disease.
202018 citationsauthor #1
LEADER Trial Eligibility and Preventable Cardiovascular Events in US Adults with Diabetes: the National Health and Nutrition Examination Surveys 2007–2016
20206 citationsauthor #3
Triglycerides and Atherosclerotic Cardiovascular Disease.
20201 citationsauthor #41
Sociodemographic and metabolic risk characteristics associated with metabolic weight categories in the Women’s Health Initiative
20203 citationsauthor #7
Preventive cardiology or cardiometabolic medicine: a new and emerging subspecialty?
20202 citationsauthor #1
Cardiovascular and cardiometabolic prevention: high-level priority in the era of COVID-19
20205 citationsauthor #2
Abstract 14434: Identification and Predictors for Cardiovascular Disease Risk Equivalents Among Adults With Diabetes Mellitus
20200 citationsauthor #8
Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology
2020112 citationsauthor #11
Faculty Opinions recommendation of Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.
20200 citationsauthor #1
Lipid treatment and goal attainment characteristics among persons with atherosclerotic cardiovascular disease in the United States
202034 citationsauthor #5
Non-HDL Cholesterol and Atherosclerotic Cardiovascular Disease.
20205 citationsauthor #41
Primary Care Physician and Cardiologist Characteristics Predicting Diagnosis and Treatment of Patients with Familial Hypercholesterolemia
20200 citationsauthor #3
REDUCE-IT ELIGIBILITY AND PREVENTABLE FIRST AND TOTAL CARDIOVASCULAR EVENTS IN THE US POPULATION: AN ANALYSIS OF THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES)
20200 citationsauthor #1
Abstract 13418: Inter-relation of Parity and Coronary Artery Calcium With Cardiovascular Disease Events: The Multi-ethnic Study of Atherosclerosis
20202 citationsauthor #7
Estimating the number of preventable cardiovascular disease events in the United States using the EMPA-REG OUTCOME trial results and National Health and Nutrition Examination Survey
20203 citationsauthor #1
CORONARY ARTERY CALCIUM PROGRESSION AND CVD RISK AMONG THOSE ON STATIN THERAPY
20200 citationsauthor #9
In Reply.
20200 citationsauthor #2
Use of non‐LDL‐C lipid‐lowering medications in patients with type 2 diabetes
20201 citationsauthor #3
Sex Differences in Coronary Artery Calcium and Mortality From Coronary Heart Disease, Cardiovascular Disease, and All Causes in Adults With Diabetes: The Coronary Calcium Consortium
202039 citationsauthor #1
REDUCE-IT Eligibility and Preventable Cardiovascular Events in the US Population (from the National Health and Nutrition Examination Survey [NHANES]).
202015 citationsauthor #1
Primary Care Physician and Cardiologist Cascade Screening Behaviors and Treatment Recommendations for Patients with Familial Hypercholesterolemia
20200 citationsauthor #4
Lifestyle Modification in the Prevention of Atherosclerotic Cardiovascular Disease.
20204 citationsauthor #41
Multisite atherosclerosis in subjects with metabolic syndrome and diabetes and relation to cardiovascular events: The Multi-Ethnic Study of Atherosclerosis.
201941 citationsauthor #10
Abstract 11695: Development and Validation of New Cardiovascular Disease Risk Scores for Patients With Diabetes Mellitus From a Pooled Cohort of the US Population
20190 citationsauthor #11

TIMELINE

1989 8 citations

1991 15 citations

1994 90 citations

1995 22 citations

1996 4 citations

1997 0 citations

1999 57 citations

2000 0 citations

2001 2,149 citations

2002 128 citations

2003 2,777 citations

2004 710 citations

2005 1,003 citations

2006 1,078 citations

2007 1,848 citations

2008 3,966 citations

2009 11,992 citations

2010 1,810 citations

2011 6,646 citations

2012 7,751 citations

2013 8,565 citations

2014 4,608 citations

2015 545 citations

2016 1,161 citations

2017 1,313 citations

2018 857 citations

2019 1,268 citations

2020 1,026 citations

2021 239 citations

2022 416 citations

Unknown 0 citations

N. Wong

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT